查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1735693

全球脑炎疫苗市场规模（按菌株、最终用户、区域覆盖范围和预测）

Global Encephalitis Vaccine Market Size By Strain (Nakayama, Beijing, P-3, SA 14-14-2), By End User (Child, Adult), By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

脑炎疫苗市场规模及预测

2024 年脑炎疫苗市场规模为 12.6913 亿美元，预计到 2032 年将达到 18.7565 亿美元，2026 年至 2032 年的复合年增长率为 5.52%。

脑炎病毒感染导致的高死亡率和发病率令人担忧，这正在提高多个地区的认知度，并推动市场成长。各种政府措施、明确的政策和充足的治疗补贴正在促进市场的成长。 《全球脑炎疫苗市场报告》对市场进行了全面评估，全面分析了关键细分市场、趋势、市场驱动因素、限制因素、竞争格局以及影响市场的关键因素。

定义全球脑炎疫苗市场

脑炎病毒是一种蚊媒黄病毒，由蚊子传播给候鸟、猪和其他脊椎动物宿主。该病毒可以透过脑炎疫苗来预防。脑炎病毒的发生率通常较低，但因地区和季节而异。脑炎疫苗可以预防该病毒。脑炎病毒可透过受感染蚊子的叮咬在人与人之间传播，在农村农业地区最为常见，其中亚太地区的病例最多。

全球脑炎疫苗市场概况

由于脑炎病毒造成的高死亡率，全球市场正以相对较高的成长率扩张。政府不断加强对儿童接种疫苗的鼓励，也推动了市场的成长。关于这些疫苗益处的宣传活动和项目的增多，也为市场带来了机会。综合来看，这些因素预计将在不久的将来增加对脑炎疫苗的需求。

目录

第一章全球脑炎疫苗市场介绍

  • 市场概览
  • 研究范围
  • 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

  • 资料探勘
  • 验证
  • 第一手资料
  • 资料来源列表

第四章全球脑炎疫苗市场展望

  • 概述
  • 市场动态
    • 驱动程式
    • 限制因素
    • 机会
  • 波特五力模型
  • 价值链分析

5. 全球脑炎疫苗市场（按菌株）

  • 概述
  • 中山
  • 北京
  • P-3
  • SA1414-2

6. 全球脑炎疫苗市场（依最终用户）

  • 概述
  • 孩子们
  • 成人

7. 全球脑炎疫苗市场（按地区）

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 世界其他地区
    • 拉丁美洲
    • 中东和非洲

8. 全球脑炎疫苗市场竞争格局

  • 概述
  • 各公司市场排名
  • 主要发展策略

第九章 公司简介

  • Liaoning Chengda
  • Valneva
  • Tiantan Biological Products
  • Sanofi Pasteur
  • Chengdu Institute of Biological Products
  • GlaxoSmithKline plc
  • Lanzhou Institute of Biological Products
  • Zhejiang Tianyuan Bio-Pharmaceutical
  • Biken

第十章 附录

  • 相关调查
简介目录
Product Code: 35644

Encephalitis Vaccine Market Size And Forecast

Encephalitis Vaccine Market size was valued at USD 1269.13 Million in 2024 and is projected to reach USD 1875.65 Million by 2032, growing at a CAGR of 5.52% from 2026-2032.

The high mortality and morbidity rate caused due to the incidence of encephalitis virus is an alarming factor that is creating awareness among multiple regions and is driving the market growth. The inititives by various government and easy policies and proper treatment aids are contributing to the growth of the market. The Global Encephalitis Vaccine Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Encephalitis Vaccine Market Definition

Encephalitis virus is a mosquito-borne Flavivirus that can be transmitted from mosquitoes to wading birds, pigs and other vertebrate hosts. This virus can be prevented using Encephalitis vaccines. The incidence rate for the Encephalitis virus is in a general low but can depend on the location and the season. This virus can be prevented using Encephalitis vaccines. As an Encephalitis infected mosquito bite can also be transmitted through humans and most commonly occurs in rural agricultural areas, thus Asia Pacific has witnessed the most number of cases.

Global Encephalitis Vaccine Market Overview

The global market is witnessing expansion at a relatively higher growth rate owing to the high mortality rate caused due to the encephalitis virus. The rise in government initiatives and recommendations to immunize children is also aiding the growth of the market. Factors such as the growing number of campaigns and programs for the improvement in awareness regarding the benefits of these vaccines are acting as an opportunity for the market. These factors, collectively, are projected to increase the demand for Encephalitis Vaccine in the near future.

Global Encephalitis Vaccine Market Segmentation Analysis

The Global Encephalitis Vaccine Market is segmented on the basis of Strain, End-User, And Geography.

Encephalitis Vaccine Market, By Strain

  • Nakayama
  • Beijing
  • P-3
  • SA 14-14-2

Based on Strain, The market is bifurcated into Nakayama, Beijing, P-3, SA 14-14-2. The Nakayama segment accounts for the largest share in the encephalitis vaccine market by strain. It is followed by beijing.

Encephalitis Vaccine Market, By End-User

  • Child
  • Adult

Based on End-User, The market is bifurcated into Child and Adult. The Encephalitis is seen in children and the adult population. Comparitively, Adult section regisets more number of individuals that are affected each year.

Encephalitis Vaccine Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the world
  • On the basis of Regional Analysis, The Global Encephalitis Vaccine Market is classified into North America, Europe, Asia Pacific, and Rest of the world. North America is anticipated to dominate the Encephalitis Vaccine Market and account for the largest share during the forecast period. Rise in investment from the government and public sector and programs to eradicate the disease from the region are the few factors expanding the growth of the market in the North American region. However, the Asia-Pacific market is anticipated to be the fastest-growing market during the forecast period. The prevalence of government-induced immunization programs, growing investment in R&D sector and entry of new vaccine manufacturers in the countries like India and China are majorly possible for the growth of the region.

Key Players

The "Global Encephalitis Vaccine Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Liaoning Chengda, Valneva, Tiantan Biological Products, Sanofi Pasteur, Chengdu Institute of Biological Products, GlaxoSmithKline plc, Lanzhou Institute of Biological Products, Zhejiang Tianyuan Bio-Pharmaceutical, and Biken. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

  • Partnerships, Collaborations and Agreements
  • April, 2020 Pfizer Inc. and Valneva SE ("Valneva") announced a collaboration to develop and commercialise Valneva's Lyme disease vaccine candidate VLA15, which is currently in Phase 2 clinical trials.
  • July 2021. GSK and Alector announce a global immuno-neurology collaboration for two clinical-stage first-in-class monoclonal antibodies for neurodegenerative diseases.
  • June 23, 2020. Sanofi and Translate Bio are expanding their collaboration to develop mRNA vaccines for all infectious diseases.
  • Mergers and Acquisitions
  • September 2020 - Sanofi announced that its acquisition of Principia Biopharma Inc. ("Principia") for $100 per share in cash has been completed.
  • April 2020. Over a year after the Rs31,700 crore mega-deal was first announced, Hindustan Unilever Ltd (HUL) has completed the merger of GlaxoSmithKline Consumer Healthcare Limited (GSKCH) with itself. HUL will distribute GSK brands such as Eno, Crocin, and Sensodyne in the country under the terms of the agreement.
  • Product Launches and Product Expansions
  • March 31, 2021. Sanofi will construct a new facility in Canada to increase the global availability of high-dose influenza vaccine.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL ENCEPHALITIS VACCINE MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL ENCEPHALITIS VACCINE MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL ENCEPHALITIS VACCINE MARKET, BY STRAIN

  • 5.1 Overview
  • 5.2 Nakayama
  • 5.3 Beijing
  • 5.4 P-3
  • 5.5 SA1414-2

6 GLOBAL ENCEPHALITIS VACCINE MARKET, BY END USER

  • 6.1 Overview
  • 6.2 Child
  • 6.3 Adult

7 GLOBAL ENCEPHALITIS VACCINE MARKET, BY GEOGRAPHY

  • 7.1 Overview
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 U.K.
    • 7.3.3 France
    • 7.3.4 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 China
    • 7.4.2 Japan
    • 7.4.3 India
    • 7.4.4 Rest of Asia Pacific
  • 7.5 Rest of the World
    • 7.5.1 Latin America
    • 7.5.2 Middle East & Africa

8 GLOBAL ENCEPHALITIS VACCINE MARKET COMPETITIVE LANDSCAPE

  • 8.1 Overview
  • 8.2 Company Market Ranking
  • 8.3 Key Development Strategies

9 COMPANY PROFILES

  • 9.1 Liaoning Chengda
    • 9.1.1 Overview
    • 9.1.2 Financial Performance
    • 9.1.3 Product Outlook
    • 9.1.4 Key Developments
  • 9.2 Valneva
    • 9.2.1 Overview
    • 9.2.2 Financial Performance
    • 9.2.3 Product Outlook
    • 9.2.4 Key Developments
  • 9.3 Tiantan Biological Products
    • 9.3.1 Overview
    • 9.3.2 Financial Performance
    • 9.3.3 Product Outlook
    • 9.3.4 Key Developments
  • 9.4 Sanofi Pasteur
    • 9.4.1 Overview
    • 9.4.2 Financial Performance
    • 9.4.3 Product Outlook
    • 9.4.4 Key Developments
  • 9.5 Chengdu Institute of Biological Products
    • 9.5.1 Overview
    • 9.5.2 Financial Performance
    • 9.5.3 Product Outlook
    • 9.5.4 Key Developments
  • 9.6 GlaxoSmithKline plc
    • 9.6.1 Overview
    • 9.6.2 Financial Performance
    • 9.6.3 Product Outlook
    • 9.6.4 Key Developments
  • 9.7 Lanzhou Institute of Biological Products
    • 9.7.1 Overview
    • 9.7.2 Financial Performance
    • 9.7.3 Product Outlook
    • 9.7.4 Key Developments
  • 9.8 Zhejiang Tianyuan Bio-Pharmaceutical
    • 9.8.1 Overview
    • 9.8.2 Financial Performance
    • 9.8.3 Product Outlook
    • 9.8.4 Key Developments
  • 9.9 Biken
    • 9.9.1 Overview
    • 9.9.2 Financial Performance
    • 9.9.3 Product Outlook
    • 9.9.4 Key Developments

10 Appendix

  • 10.1 Related Research